Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Nightingale Health

1,68 EUR

-0,71 %

4.672 følger denne virksomhed
Kunde

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Investorkonsensus
Sammenligne
-0,71 %
-14,72 %
-18,05 %
-28,66 %
-29,41 %
-39,35 %
+62,48 %
-
-67,38 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Læs mere
Markedsværdi
102,38 mio. EUR
Aktieomsætning
57,94 t EUR
P/E (adj.) (26e)
-6,17
EV/EBIT (adj.) (26e)
-3,73
P/B (26e)
1,95
EV/S (26e)
8,23
Udbytteafkast, % (26e)
-
Dækning
Anbefaling
Reducer
Kursmål
2.50 EUR
Opdateret
19.09.2025
Disclaimer
Antti Siltanen
Antti Luiro
Antti Luiro, Antti Siltanen
Vis mere
Seneste analyse

Seneste analyse

Udgivelse: 19.09.2025

Seneste omfattende analyse

Udgivelse: 13.06.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
5.3
2026

Delårsrapport Q2'26

Risiko
Forretningsrisiko
Værdiansættelsesrisiko
Lav
Høj
Alle
Analyse
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Nightingale tager et skridt fremad i New York
Analytikerkommentar10.2.2026, 05.38 af
Antti Siltanen

Nightingale tager et skridt fremad i New York

New Yorks laboratorietilladelse gør det muligt at tilbyde tests til sundhedsvæsenet uden separat FDA-godkendelse.

Nightingale Health
Selskabsmeddelelse9.2.2026, 19.30

Inside information: Nightingale Health achieves major milestone in the United States: New York laboratory now holds a clinical laboratory permit from New York State

Nightingale Health
Another welfare services country is piloting Nightingale's technology
Analytikerkommentar18.12.2025, 17.54 af
Antti Luiro, Antti Siltanen

Another welfare services country is piloting Nightingale's technology

The North Karelia wellbeing services county is piloting Nightingale's blood analysis technology.

Nightingale Health

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse18.12.2025, 13.00

North Karelia Wellbeing Services County adopts Nightingale Health’s disease risk assessment as part of public healthcare in Finland

Nightingale Health
New study on benefits of Nightingale blood test in identifying cardiovascular disease risk
Analytikerkommentar18.12.2025, 08.14 af
Antti Luiro, Antti Siltanen

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

A new study shows that the company's blood test can improve the detection of risk factors for heart attacks and strokes.

Nightingale Health
Pressemeddelelse17.12.2025, 07.30

Landmark study: Nightingale Health’s blood test can improve prevention of heart attacks and strokes by 44% compared to current clinical practice

Nightingale Health
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video16.12.2025, 07.30

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Changes in Nightingale’s management team continue
Analytikerkommentar15.12.2025, 07.59 af
Antti Luiro, Antti Siltanen

Changes in Nightingale’s management team continue

In light of the news, Nightingale is rebuilding its management team to better accelerate growth in its healthcare business.

Nightingale Health
Selskabsmeddelelse12.12.2025, 12.55

Nightingale Health Plc restructures Management Team to accelerate healthcare business growth

Nightingale Health
Nightingale's CFO departs suddenly
Analytikerkommentar9.12.2025, 05.53 af
Antti Luiro, Antti Siltanen

Nightingale's CFO departs suddenly

The rapid change came as a surprise to us and appears to have occurred at the company's initiative, although the exact reasons remain unclear due to the concise announcement.

Nightingale Health
Selskabsmeddelelse8.12.2025, 08.35

Change in Nightingale Health Plc’s Management Team

Nightingale Health
Nightingale expands its strategic partnership with Terveystalo
Analytikerkommentar27.11.2025, 09.12 af
Antti Luiro

Nightingale expands its strategic partnership with Terveystalo

With the new agreement, Nightingale's blood analysis technology will be made available to all Terveystalo customer groups, whereas previously it has mainly been used in health check-ups for occupational health customers.

Nightingale Health
Pressemeddelelse26.11.2025, 09.00

Terveystalo and Nightingale Health deepen strategic partnership – preventive healthcare available to all Terveystalo customers in Finland

Nightingale Health
Pressemeddelelse20.11.2025, 08.00

Nightingale Health enables access to world’s largest metabolomics dataset through UK Biobank collaboration

Nightingale Health
Selskabsmeddelelse6.11.2025, 15.10

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Nightingale Health
Nightingale strengthens its research offering through strategic partnership
Analytikerkommentar5.11.2025, 14.59 af
Antti Luiro, Antti Siltanen

Nightingale strengthens its research offering through strategic partnership

Through this partnership, Nightingale will integrate Alamar's brain health proteomics technology into its multiomics offering.

Nightingale Health
Pressemeddelelse5.11.2025, 10.50

Nightingale Health partners with Alamar Biosciences to expand its unique multiomics offering with ultra-sensitive proteomics for brain health

Nightingale Health
Selskabsmeddelelse2.10.2025, 12.30

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health
Selskabsmeddelelse2.10.2025, 06.00

Nightingale Health’s Annual Report for financial year 2024–2025 has been published

Nightingale Health
Nightingale’s service expands again with a new risk prediction
Analytikerkommentar26.9.2025, 07.16 af
Antti Luiro

Nightingale’s service expands again with a new risk prediction

Nightingale Health announced on Thursday the launch of a new risk detection tool that detects a high risk of dangerously high levels of lipoprotein (a), also known as Lp(a).

Nightingale Health
Forumopdateringer
Inderes Sisäpiiritieto: Merkittävä edistysaskel Yhdysvalloissa - Nightingale Healthin... Nightingale Health Oyj | Sisäpiiritieto | 09.02.2026 klo 21:30:00 EETNightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), sairastumisriskien tunnistamisen ja ennaltaehkäisevän ....
9.2.2026, 19.34
af Critter
29
Jeg ønsker ikke at styre aktiekursen, men mange kender ikke rigtig NG’s potentiale/historik. Jeg kender dette meget indgående, og derfor har jeg lavet dette AI-resumé. Mange tror, at virksomheden ikke laver noget som helst og bare sidder og spiser tacos på kontoret om fredagen. Det...
11.2.2026, 16.55
af Ossi
13
Relevante AI-spillere nævnt, NH er med.
10.2.2026, 07.04
af Puutaheinää
10
Grunden er, at den markedspris, aktionærerne har sat på selskabet, stadig er hundrede millioner euro for et selskab med en omsætning på seks millioner og et underskud på næsten tyve millioner. Der er altså stadig masser af plads til fald.
6.2.2026, 09.01
af Pertti
7
Inderes Nightingalelle edistysaskel New Yorkissa - Inderes New Yorkin laboratoriolupa mahdollistaa testien tarjoamisen terveydenhuollolle ilman erillistä FDA-hyväksyntää.
10.2.2026, 05.45
af Pertti
5
Rapporten var åbenbart allerede blevet offentliggjort kl. 01.00. Så ved et hurtigt blik ønsker man et centraliseret system i Finland, hvor nationale sundhedsdata indsamles i et standardiseret format. Dette understøtter jo Nightingales fremgangsmåde. Forhåbentlig følger verden efter...
10.2.2026, 06.46
af Salkkumies
4
God start for mit vedkommende, da jeg er nede med omkring 15 % fra entry på ca. tre uger.
6.2.2026, 09.49
af TomPettynyt
2
Besøg forummet
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.